Stock fact sheet · data as of

SANUWAVE Health Inc. (SNWV): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Value

Close5.14
GLS fair value34.467 of 9 models
Margin of safety+85%price below fair value
Wheel Score39No optionscapped: no options
Health4/9Piotroski F-score
Moat4.6/10GLS 10-year score
Market cap$44M50k shares a day
Implied vol.-no listed options
P/E3.1EPS 1.66
Dividend yieldnone
Beta1.46moves more than the market
Next earnings6 Nov 2026in 21 days

Is SNWV undervalued?

SANUWAVE Health Inc. (SNWV) closed at 5.14 on 16 Oct 2026. The GLS average fair value - the simple average of the 7 valuation models that produced a positive number - is 34.46, which puts the price 85% below it. 6 of the 7 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.

The 7 models disagree widely: Graham Number gives 3.48 while Graham Growth gives 95.18. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.

The nightly engine files SNWV under Value: positive earnings at a P/E of 18 or less.

Nine valuation models for SNWV

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number3.48-32%The most a defensive investor pays for the earnings and book value per share
Graham Growth95.18+1752%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch41.60+709%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth49.09+855%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap10.79+110%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time22.59+340%Eight years of compounded free cash flow: the price at which the business pays for itself
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV18.49+260%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)-1.29-125%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target54.00+951%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: SNWV passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 4.6 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are high - ROIC 48.0%, ROE 729.6%, ROA 31.6% - with debt at 14.19 times equity and a free-cash-flow yield of 14.0%. Debt of 14.19 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.

SANUWAVE Health Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from System Revenue 95%, Extended Warranty 3%, Other Revenue 2% (quarter Q2 FY2026).

Institutional ownership scores 6/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score4 / 9ROIC48.0%
GLS Moat4.6 / 10ROE729.6%
Debt / equity14.19ROA31.6%
Free-cash-flow yield14.0%Payout ratio0%
Institutions6 / 10Insiders · Congress1 · 5 / 10

Wheel Score 39: No options

SNWV has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 50k shares a day on a market cap of $44M, with a beta of 1.46 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 5 of 20.

PartPointsFrom
Value25 / 2585% margin of safety
Health9 / 20Piotroski 4/9
Moat7 / 15moat 4.6/10
Premium0 / 20no option data
Stability5 / 2050k shares/day, $44M cap, beta 1.46

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 6 Nov 2026, 21 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to SANUWAVE Health Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
XTNT
Xtant Medical Holdings, Inc.
0.31850.2440-31%16No options$45M
SRTS
Sensus Healthcare, Inc.
2.863.03+6%36Weak$47M
POSC
Positron Corporation
1.50--22No options$49M
TELA
TELA Bio, Inc.
1.101.19+8%36Weak$49M
COCH
Envoy Medical, Inc.
0.64470.0239-2603%11No options$50M
NNOX
Nano-X Imaging Ltd.
0.4911--31Weak$39M
MYO
Myomo, Inc.
1.30--31Weak$51M
RPID
Rapid Micro Biosystems, Inc.
0.8173--24No options$37M
CVRX
CVRx, Inc.
1.39--36Weak$37M
QTI
QT Imaging Holdings, Inc.
2.50--32No options$37M
MBOT
Microbot Medical Inc.
0.95000.0728-1205%25Weak$64M
NSYS
Nortech Systems Incorporated
10.3215.29+33%39No options$29M

⚖ Compare SNWV with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about SNWV

Is SNWV undervalued right now?

By the GLS models, yes: at 5.14 the stock is 85% below the average fair value of 34.46 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of SNWV and what does it mean?

SNWV has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for SNWV?

34.46 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does SANUWAVE Health Inc. report earnings next?

The next earnings report is due on 6 Nov 2026, 21 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does SNWV have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on SNWV, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.